Skip to main content
PLOS One logoLink to PLOS One
. 2022 Mar 8;17(3):e0264203. doi: 10.1371/journal.pone.0264203

Effects of intra-articular Platelet-Rich Plasma (PRP) injections on osteoarthritis in the thumb basal joint and scaphoidtrapeziotrapezoidal joint

Elin Swärd 1,2, Maria Wilcke 1,2,*
Editor: Gabriel de Araújo3
PMCID: PMC8903265  PMID: 35259167

Abstract

Intra-articular injection of platelet rich plasma (PRP) has been reported to decrease pain and improve function in knee osteoarthritis. There are few reports on the effect of PRP in the treatment of osteoarthritis in the hand. Our aim was to evaluate the effect of PRP-injections on pain and functional outcome in the short-term for osteoarthritis in the thumb basal joint and scaphoidtrapeziotrapezoidal (STT) joint. A retrospective analysis was performed of 29 patients treated with intra-articular PRP injection for painful osteoarthritis in the thumb basal joint (21 patients) or STT joint (eight patients). The patients received two consecutive, radiologically guided PRP injections at an interval of 3–4 weeks. Pain at rest and on load (numerical rating scale (NRS) 0–10), Patient-rated Wrist and Hand Evaluation (PRWHE) score (0–100), grip strength (Jamar) and key pinch were recorded pre-injection and 3 months after the second injection. Mean age was 63 (range 34–86) years and 17 patients were women. We used generalized estimating equations (GEE) to analyze the effect on the outcome variables. Possible predictors were included in the model (high pain level pre-injection, gender, age, manually demanding work, affected joint (thumb base or STT) and use of analgesic). The GEE analysis showed that PRP injections had no effect on reported pain, PRWHE score, grip strength or key pinch. 16/28 patients experience a positive effect according to a yes/no question. The short-term effect of PRP for osteoarthritis in the thumb base and STT-joint is doubtful and needs to be properly investigated in placebo-controlled studies.

Introduction

Osteoarthritis in the thumb basal joint and scaphoidtrapeziotrapezoidal joint is very common, increases with age and may cause substantial disability in the ageing population [13]. Non-operative treatment includes patient education in joint protection, splints, analgesics, and intra-articular corticosteroid injections. Successful conservative treatment that delays or reduces the need for surgery is of great value for both the individual and the public healthcare.

Intra-articular injection of platelet rich plasma (PRP) has been shown to relieve pain and improve functional outcome compared to hyaluronic acid or saline in knee osteoarthritis [47]. PRP is derived by centrifugation of autologous blood to separate the plasma that contains high concentrations of platelets. Platelets contain large number of growth factors and some of these regulate selected biological processes in tissue repair and may have an anti-inflammatory effect. It has been suggested that fibrinogen in PRP may be activated to form a fibrin matrix that may fill cartilage lesions and that PRP may have positive effects on cartilage repair [8].

There are few previous studies on the effect of PRP for osteoarthritis in the hand. One noncomparative pilot study of 10 patients with thumb base osteoarthritis reported decreased pain [9]. A randomized comparison between PRP and intra-articular corticosteroids [10] in a total of 33 patients with thumb base osteoarthritis, concluded that PRP achieved reduced pain and improved function up to 12 months.

We hypothesized that PRP injections would decrease patient-reported pain in the short term for osteoarthritis in the thumb basal joint and STT-joint.

Materials and methods

This is a retrospective case series based on medical records of all patients that received PRP treatment for radiologically and clinically verified osteoarthritis in the thumb basal joint or STT-joint at a specialized Hand Surgery unit between September 1st2018 and September 30th2019 (selection criteria). The Arthrex ACP double-syringe system was used for preparation and injection of the PRP. Fifteen milliliters of venous blood were drawn from each patient and centrifugated at 1500 rpm for five minutes as described by the Arthrex double-syringe manual. The patients received two consecutive PRP injections of 0.5–2 ml at an interval of 3–4 weeks according to recommendations from the manufacturer (Arthrex). The injections were performed at outpatient visits, under sterile conditions and under fluoroscopic guidance, to assure that the PRP was deposited intraarticularly. The patients could resume work and daily activities immediately after the injection as tolerated. There was no specific post-injection hand exercise protocol.

The assessment before and after the PRP injections were standardized. Pain at rest and on load rated by a numerical rating scale (NRS) 0–10 points, Patient-Rated Wrist and Hand Evaluation (PRWHE) score (0–100 points) [11,12], grip strength (Jamar) and key pinch was recorded pre-injection, before the second injection and three months after the second injection (i.e., four months after the first injection). Key pinch and grip strength were measured three times, of which the mean values were recorded. Patients that did not attend the assessment after four months were excluded due to lack of data. There were no other exclusion criteria.

The severeness of the osteoarthritis was classified according to Eaton and Littler [13] for thumb basal osteoarthritis and according to the classification system described by White et al. [14] for STT osteoarthritis.

The study was approved by the Swedish Ethical Review Authority (D.nr 2020–02040).

Statistics

Pain NRS on load was the primary outcome. Pain NRS scores and PRWE are reported as median (Interquartile range (IQR)) and continuous variables (i.e., key pinch and grip strength) as mean (standard deviation (SD)). In patients with chronic musculoskeletal pain, a reduction of two points in the NRS is considered as a substantial improvement (“much better”) by the patients and is recommended as a clinically important outcome [15]. To detect a mean improvement of two points in pain on load NRS (0–10), estimated SD 2 (based on previous reports [9,16]) (Power 80%, p = 0.05), 10 patients are required. Hence the sample size was regarded as sufficient.

To analyze the repeated measurements, we used generalized estimating equations (GEE) with robust estimator covariances matrix, independent working correlation matrix (according to lowest QICC) and a linear model for all variables. High pre-injection pain level (≥5 pain at rest, based on the 75th quartile), gender, age, manually demanding work, affected joint (thumb base or STT), and use of analgesic were included as possible predictors in the model. The changes in outcome variables over time and the effects on the predictors are presented as beta coefficient (β) with 95%CI. The statistical software used was SPSS® version 28.

Results

Thirty-three patients had received PRP treatment. Four patients did not attend the 3-months visit and were excluded. The mean age of the remaining 29 patients was 63 (range 34–86) years. Seventeen patients were women. Twelve patients were retired, one patient was on sick leave (for unrelated reasons). Of the 16 work-active patients, four patients had administrative work and 12 manually demanding work. Twenty-one patients had thumb basal joint osteoarthritis and eight patients had STT-joint osteoarthritis. Table 1 presents the grading of the osteoarthritis.

Table 1. Localization and grading of the osteoarthritis.

Localization of osteoarthritis Grade n =
Thumb basal joint Eaton 1 2
Eaton 2 4
Eaton 3 12
Eaton 41 3
Scaphoidtrapeziotrapezoidal joint White 1 1
White 3 7

1No symptoms from the STT-joint.

Twenty-two patients had used a splint prior to the PRP treatment, and 20 patients had previously tried corticosteroid injections. Two patients were prescribed analgesics for pain in the thumb base or STT-joint at/in conjunction with the first injection, seven patients frequently used analgesics for unrelated causes and 20 patients were not prescribed any analgesics during the study period.

The values of the outcome variables at the different assessments are presented in Table 2.

Table 2. Pain, patient-rated results and strength.

Pain at rest NRS (0–10) Pain on load NRS (0–10) PRWHE (0–100) Grip strength (kg) Key pinch (kg)
Preinjection 2 (1–5) 8 (6–9) 65 (55–77) 23 (13) 5.5 (2.5)
2nd injection 0 (0–4) 7 (4–10) 60 (43–77) 22 (13) 5.8 (2.9)
3 months after 2nd injection 1 (0–3) 6 (4–9) 54 (40–81) 23 (14) 6.0 (2.9)

Pain and PRWHE values are presented as median (IQR). Grip strength and key pinch values are presented as mean (SD).

Table 3 presents the results of the GEE analyses. A high pre-injection pain level predicted more pain at rest and on load at follow-up (β = 4.0(3.0–4.9) and 1.9(0.8–2.9), respectively). When corrected for pre-injection pain level, there was no significant improvement of pain at rest or on load after PRP injection. A high pre-injection pain level and age 65 years or older predicted a worse PRWHE score (β = 22(12–31) and (β = 12(2–22), respectively) but the PRP injection did not affect PRWHE score. A high pre-injection pain level, age over 65 years and female gender predicted lesser grip strength (β = -5(-12- -24), -8(-14- -2) and -18(-12- -24), respectively) and key pinch (β = -1.8(-2.7–1.0), -3.3(-4.9- -1.6) and -2.6(-1.1–4.1) respectively). There was a significant decrease of grip strength at the second PRP injection but not at the final assessment and there was no change in key pinch after PRP injection. Manually demanding work, affected joint, and use of analgesic did not affect the outcome variables.

Table 3. Effect of PRP injection on pain, patient-rated result and strength.

Beta coefficients for improvement (95%CI)
Pain at rest NRS* Pain on load NRS* PRWHE ** Grip strength*** Key pinch***
Preinjektion - 2nd injection 0.61(-0.43–1.66) -0.73(-1.8–0.37) 2(-10-10) -2.86(-5.44–0.02) -0.24(-0.94–0.47)
Preinjektion—3 months after 2nd injection 0.44(-0.50–1.38) -0.98(-2.17–0.20) 0(-5-10) -1.72(-5.08–1.64) 0.10(-0.85–0.97)

*corrected for high pain level pre-injection.

**corrected for high pain level pre-injection and age.

*** corrected for high pain level pre-injection, age and gender.

Beta coefficient: Expected population average change of the outcome variable between the assessments.

Of 28 patients that had answered the question if they experienced a positive effect of the injections, 16 answered “yes”, 9 “no” and 3 answered “I don’t know”. 15 patients requested a new PRP injection, and two patients wished for a corticosteroid injection at the follow-up 4 months after the first injection. There were no recorded infections or other adverse events.

Discussion

We could not find a significant effect on patient-reported pain, hand disability or strength in the short-term after intra-articular PRP injections for osteoarthritis in the thumb basal joint or STT-joint. On a yes/no question of experienced improvement, more than half of the patients said yes. However, even when possible confounders were not taken into account, the mean individual reduction in pain NRS did not amount to two points (Table 2), corresponding to a substantial improvement [15].

There are few reports of the effect of PRP on osteoarthritis in the hand. Malahias el al. [10] performed a blinded randomized comparison between two PRP injections with a two week’s interval (16 patients) and intra-articular corticosteroid injections (17 patients) for thumb base osteoarthritis and reported a decrease in pain visual analogue scale (VAS) from 75 to 40 (out of 100) and improved quick Disabilities of the Arm, Shoulder and Hand (qDASH) score from 50 to 33 (out of 100) at 3 months in the PRP group. In comparison, the corticosteroid group also reported better VAS (from 70 to 20 out of 100) at 3 months but after 12 months, the PRP group reported significantly less pain and better function than the corticosteroid group. The reported improvement in pain and quickDASH almost are almost in line with trapeziectomy after one year [16], hence a result very dissimilar to ours. Malahias et al. used PRP that was prepared manually at a local hospital laboratory, while we used a commercial kit (Arthrex ACP double-syringe system). Therefore, the concentration of platelets may differ.

Loibl et al. [9] evaluated 10 patients with thumb basal joint osteoarthritis treated with two intra-articular PRP (Arthrex ACP double-syringe system) injections 4 weeks apart and reported decreased pain with activity (VAS) from 6.2 to 4.0 after three months and improvement in the Disabilities of the arm, shoulder, and hand (DASH) score from 33 to 20 (out of 100) but unaffected grip strength and pinch strength. After 6 months, VAS had increased to 5.5 and DASH to 27.

One possible explanation to the fact that our result opposes Malahias et al. and Lobli et al. could be that the latter studies used rather simple statistical analyses and have not corrected the results for confounding factors such as pre-injection pain level, gender, age etc. Malahias et al. has a randomized design which may compensate for potential confounders. However, PRP is not compared to placebo but to corticosteroid and one should be aware of that, despite widely used, there is lack of evidence that corticosteroid injections have effect on pain and function compared to placebo for thumb basal joint osteoarthritis [17] as well as in other joints [18]. Hence, the observed effect in the previous studies could be placebo. It has been shown that placebo is effective in the treatment of osteoarthritis, especially for pain, stiffness, and self-reported function and the placebo for new treatments (like PRP) tend to be more effective [19]. The placebo effect increases with increase baseline pain severity [19]. In this study, we found that the pain level before PRP treatment had the greatest impact on the outcome variables. Hence it is a strength of the study that pain level before injection is corrected for in the analysis. In addition to a potential placebo effect, chance regression to the mean and natural disease remission are possible explanations to the previous observed results of PRP injections that could not be reproduced in our study.

One can question why our study showed no effect of PRP for thumb basal and STT-joint osteoarthritis when placebo-controlled studies have shown that PRP has effect for knee osteoarthritis [4,5]. We have no plausible explanation, and we suggest that this study alone should not be used to dismiss PRP injections for osteoarthritis in the hand, but the effect needs to be further and properly investigated in placebo-controlled studies.

Psychological factors may have an impact on pain outcome. Anxiety, depression, and pain catastrophizing has been shown to predict poor outcome after hand surgery [20,21]. It is reasonable that psychological factors similarly may affect the result of injection treatment. A high rated pain at rest in patients with osteoarthritis can some extent be considered a proxy for pain catastrophizing and is therefore to some degree included as predictor in the analysis. However, a weakness of the study is that we have not been able to correct the results for depressions and anxiety.

This study has several other limitations. Obviously, it is a retrospective observational study with associated risk for uncontrolled biases. The data was collected from medical records and lack forinformation about some factors that may affect PROMs. For example, we have no information on the extent to which patients used splints and of over-tha-counter analgesics post-injection. Further, the studied sample is relatively small. However, it is not small compared to the previous studies discussed [9,10] that, has shown a significant effect of PRP, hence it is not likely that the sample size explains the absence of a detectable effect in this study. Another limitation is the short follow-up. Hypothetically there could a late-onsetting effect. However, we consider that scenario unlikely.

Unlike intra-articular corticosteroid injections that may have a harmful effect on cartilage [22,23], PRP have no documented side effects [6,8] and does not increase the risk of adverse events compared with injection of hyaluronic acid or saline [24]. PRP is not classified as a drug and its use is therefore not restricted by any regulations. Consequently, there has been a flurry of various applications of this harmless and potentially salutary injection, from musculoskeletal disorders to cosmetics. Hence, the risk with PRP is rather an overuse of a costly and perhaps ineffective treatment and therefore it is important to establish if there is a true therapeutic effect. The result of this study contradicts the hypothesis that PRP injections have an effect in terms of pain relief, disability, or strength for osteoarthritis in the thumb basal joint or STT-joint.

Supporting information

S1 Dataset

(XLSX)

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Armstrong AL, Hunter JB, Davis TR. The prevalence of degenerative arthritis of the base of the thumb in post-menopausal women. J Hand Surg Br 1994;19(3):340‐341. doi: 10.1016/0266-7681(94)90085-x [DOI] [PubMed] [Google Scholar]
  • 2.Dahaghin S, Bierma-Zeinstra SM, Ginai AZ, Pols HA, Hazes JM, Koes BW. Prevalence and pattern of radiographic hand osteoarthritis and association with pain and disability (the Rotterdam study) Ann Rheum Dis 2005;64(5):682‐687. doi: 10.1136/ard.2004.023564 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Moriatis Wolf J, Turkiewicz A, Atroshi I, Englund M. Prevalence of doctor-diagnosed thumb carpometacarpal joint osteoarthritis: an analysis of Swedish health care. Arthritis Care Res (Hoboken) 2014;66(6):961‐965. doi: 10.1002/acr.22250 [DOI] [PubMed] [Google Scholar]
  • 4.Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med 2013;41(2):356‐364. doi: 10.1177/0363546512471299 [DOI] [PubMed] [Google Scholar]
  • 5.Smith PA. Intra-articular Autologous Conditioned Plasma Injections Provide Safe and Efficacious Treatment for Knee Osteoarthritis: An FDA-Sanctioned, Randomized, Double-blind, Placebo-controlled Clinical Trial. Am J Sports Med 2016;44(4):884‐891. doi: 10.1177/0363546515624678 [DOI] [PubMed] [Google Scholar]
  • 6.Xing D, Wang B, Zhang W, Yang Z, Hou Y, Chen Y, et al. Intra-articular platelet-rich plasma injections for knee osteoarthritis: An overview of systematic reviews and risk of bias considerations. Int J Rheum Dis 2017;20(11):1612–1630. doi: 10.1111/1756-185X.13233 [DOI] [PubMed] [Google Scholar]
  • 7.Zhao K, Liu YS, Nie LY, Qian LN, Nie NF, Leptihn S, et al. The influence of sample size and gender composition on the meta-analysis conclusion of platelet-rich plasma treatment for osteoarthritis. J Orthop Translat 2019;22:34–42. doi: 10.1016/j.jot.2019.10.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Xie X, Zhang C, Tuan RS. Biology of platelet-rich plasma and its clinical application in cartilage repair. Arthritis Res Ther 2014;16(1):204. doi: 10.1186/ar4493 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Loibl M, Lang S, Dendl LM, Nerlich M, Angele P, Gehmert S, et al. Leukocyte-Reduced Platelet-Rich Plasma Treatment of Basal Thumb Arthritis: A Pilot Study. Biomed Res Int 2016;2016:9262909. doi: 10.1155/2016/9262909 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Malahias MA, Roumeliotis L, Nikolaou VS, Chronopoulos E, Sourlas I, Babis GC. Platelet-Rich Plasma versus Corticosteroid Intra-Articular Injections for the Treatment of Trapeziometacarpal Arthritis: A Prospective Randomized Controlled Clinical Trial. Cartilage 2021. Jan;12(1):51–61. doi: 10.1177/1947603518805230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.MacDermid JC, Turgeon T, Richards RS, Beadle M, Roth JH. Patient rating of wrist pain and disability: A reliable and valid measurement tool. J Orthop Trauma 1998;12(8): 577–86. doi: 10.1097/00005131-199811000-00009 [DOI] [PubMed] [Google Scholar]
  • 12.Wilcke M, Abbaszadegan H, Adolphson P. Evaluation of a Swedish version of the Patient-Rated Wrist Evaluation (PRWE) outcome questionnaire; good responsiveness, validity, and reliability, in 99 patients recovering from a fracture of the distal radius. Scand J Plastic Reconstr Surg Hand Surg 2009;43(2):94–101. [DOI] [PubMed] [Google Scholar]
  • 13.Eaton R.G, Littler J.W. Ligament Reconstruction for the Painful Thumb Carpometacarpal Joint, The Journal of Bone & Joint Surgery: December 1973. —Volume 55—Issue 8—p 1655–1666. [PubMed] [Google Scholar]
  • 14.White L, Clavijo J, Gilula LA, Wollstein R. Classification system for isolated arthritis of the scaphotrapeziotrapezoidal joint. Scand J Plast Reconstr Surg Hand Surg 2010. Apr;44(2):112–7. doi: 10.3109/02844311003675388 [DOI] [PubMed] [Google Scholar]
  • 15.Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 2004. Aug;8(4):283–91. doi: 10.1016/j.ejpain.2003.09.004 [DOI] [PubMed] [Google Scholar]
  • 16.Wilcke M, Roginski M, Åström M, Arner M. A registry-based analysis of the patient reported outcome after surgery for trapeziometacarpal joint osteoarthritis. BMC Musculoskel Dis 2020:21: 63. doi: 10.1186/s12891-020-3045-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Riley N, Vella-Baldacchino M, Thurley N, Hopewell S, Carr AJ, Dean BJF. Injection therapy for base of thumb osteoarthritis: a systematic review and meta-analysis. BMJ Open 2019. Sep 11;9(9):e027507. doi: 10.1136/bmjopen-2018-027507 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ayub S, Kaur J, Hui M, Espahbodi S, Hall M, Doherty M, et al. Efficacy and safety of multiple intra-articular corticosteroid injections for osteoarthritis—a systematic review and meta-analysis of randomized controlled trials and observational studies. Rheumatology (Oxford). 2021. Jan 12:keaa808. doi: 10.1093/rheumatology/keaa808 Epub ahead of print. . [DOI] [PubMed] [Google Scholar]
  • 19.Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008; 67(12): 1716–23. doi: 10.1136/ard.2008.092015 [DOI] [PubMed] [Google Scholar]
  • 20.Egloff N, Wegmann B, Juon B, Stauber S, von Känel R, Vögelin E. The impact of anxiety and depressive symptoms on chronic pain in conservatively and operatively treated hand surgery patients. J Pain Res. 2017; 31; 10: 259–263. doi: 10.2147/JPR.S116674 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Mosegaard SB, Stilling M, Hansen TB. Higher preoperative pain catastrophizing increases the risk of low patient reported satisfaction after carpal tunnel release: a prospective study. BMC Musculoskelet Disord. 2020: 18; 21(1): 42. doi: 10.1186/s12891-020-3058-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Wernecke C, Braun HJ, Dragoo JL. The Effect of Intra-articular Corticosteroids on Articular Cartilage: A Systematic Review. Orthop J Sports Med 2015;3(5):2325967115581163. doi: 10.1177/2325967115581163 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.McAlindon TE, LaValley MP, Harvey WF, et al. Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients with Knee Osteoarthritis: A Randomized Clinical Trial. JAMA 2017;317(19):1967–1975. doi: 10.1001/jama.2017.5283 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Dai WL, Zhou AG, Zhang H, Zhang J. Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials. Arthroscopy 2017;33(3):659‐670. doi: 10.1016/j.arthro.2016.09.024 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Gabriel de Araújo

15 Sep 2021

PONE-D-21-21631Effects of intra-articular Platelet-Rich Plasma (PRP) injections on osteoarthritis in the thumb basal joint and scaphoidtrapeziotrapezoidal joint.PLOS ONE

Dear Dr. Wilcke,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 30 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Gabriel de Araújo, M.D., MSc

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please ensure that you include a title page within your main document. You should list all authors and all affiliations as per our author instructions and clearly indicate the corresponding author

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a relatively short and simple analysis of available data to answer whether PRP injections improve osteoarthritis in the thumb basal joint and scaphoidtrapeziotrapezoidal joint. The organization is clear and the short paper is well written. I submit the findings may be potentially useful but it is a one-arm study which is also much more open to bias and misleading conclusions. A main question I have is whether there is enough substantial material for a publication given the paper is relatively much shorter than others I have refereed in the journal and the data is very simply analyzed.

I focus on the statistical aspects for the study. Overall, I find the analysis relatively simple which can be particularly problematic when the sample size is small. Some particular concerns are

a) There was mention about excluding patients from the study because they had incomplete data. It is not clear what exclusion rule was used whether the missingness had something to do with the disease progression or the pain the patient is suffering. Are data missing at random or completely missing at random or otherwise? Statistical methods will then have to specially used for different types of missingness;

b) There are statistical tests that are more reliable for analysis small sample data that are more reliable; permutation tests may be better alternatives. Similarly, Shapiro-Wilk’s test results on whether the data are normally distributed can also be questionable for small data set;

and

c) There were demographic data or covariates on the patients but there was no discussion if some of them play a role in explaining the findings the authors obtained.

Reviewer #2: Well written and pleasant to read paper.

Introduction:

- How is it relevant to only focus on the short-term effects of this treatment? I'm not sure it is, but please explain. As CMC1 OA is a chronic condition (we will all get osteoarthritis of the thumb if we live long enough), we should focus on treatments that have long-term benefits. Most likely a "quick fix" with an injection or surgical intervention is not the solution.

- Please change "conservative treatment" to "non-operative treatment".

Methods:

- The 3-4 weeks interval between the injections: please explain how you chose this time interval.

- Symptom intensity of CMC1 OA is strongly related to the influence of psychosocial aspects; patients with greater symptoms of catastrophic thinking and depression have greater pain intensity. In many multivariable analysis, these are the strongest contributors to several outcomes including pain (see papers of Becker et al., Wilkens et al., or Prof. Ring). At least, this must be mentioned as it could lead to a potential bias in the findings of the current paper.

- How did you estimate an SD of 2 points for NRS pain?

- What where the inclusion criteria or selection criteria for patients to receive a PRP injection?

Results & Discussion:

- Please write out "thirty-three" and other numbers that are at the beginning of a sentence.

- Line 111-112: these results don't exceed the MCID. Although there is some variety among studies about the MCID for pain scores (NRS/VAS), most agree that an improvement of 1 point is not enough to reach an MCID in outcome (Danoff 2018, Lee 2003). Even the study referred to in this manuscript (Salaffi et al.) supports the use of a "much better" improvement on pain relief as a clinically important outcome: and that is 2 points. I think the authors must revise this point and their conclusion. They found a significant but not a clinically important difference in pain improvement. This is in line with the other study findings that shows no difference in PROMs. And it does not support the (costly) use of PRP for patients with CMC1 OA seeking specialty care.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Mar 8;17(3):e0264203. doi: 10.1371/journal.pone.0264203.r002

Author response to Decision Letter 0


6 Oct 2021

Thank you for a valuable review. Below we address the reviewers’ concerns point by point.

Reviewer #1:

I focus on the statistical aspects for the study. Overall, I find the analysis relatively simple which can be particularly problematic when the sample size is small.

We have addressed the reviewer’s concern about too simple statistical analysis and with help from a biomedical statistician, we have remade the analysis with a GEE model. This made a significant difference since the formerly significant improvement of pain was no longer significant after the confounding predictors were considered in the analysis. Hence, the conclusion and a major part of the discussion is revised.

Some particular concerns are

a) There was mention about excluding patients from the study because they had incomplete data. It is not clear what exclusion rule was used whether the missingness had something to do with the disease progression or the pain the patient is suffering. Are data missing at random or completely missing at random or otherwise? Statistical methods will then have to specially used for different types of missingness;

Four patients had to be excluded since they did not attend the 3 months assessment. We now write this more clearly in line 62-64. The former wording was unclear. The reason for not attending could not be found in the medical records. We consider them missing at random. After ha have redone the analyses with correction for predictors (please see below), a potential difference in the excluded patient compared to the analysed sample, should not be a problem.

b) There are statistical tests that are more reliable for analysis small sample data that are more reliable; permutation tests may be better alternatives. Similarly, Shapiro-Wilk’s test results on whether the data are normally distributed can also be questionable for small data set;

We now use GEE for analyses instead so this should not be an issue.

and

c) There were demographic data or covariates on the patients but there was no discussion if some of them play a role in explaining the findings the authors obtained.

The covariates/possible predictors are now included in a GEE model.

Reviewer #2:

Well written and pleasant to read paper.

Introduction:

- How is it relevant to only focus on the short-term effects of this treatment? I'm not sure it is, but please explain. As CMC1 OA is a chronic condition (we will all get osteoarthritis of the thumb if we live long enough), we should focus on treatments that have long-term benefits. Most likely a "quick fix" with an injection or surgical intervention is not the solution.

We believe that the short-term aspect is relevant since injections are assumed to foremost have a short-term effect. We did not have long-term data and we agree that the short-term follow-up is a limitation and mention this in the discussion line 173-174.

- Please change "conservative treatment" to "non-operative treatment".

This is now changed.

Methods:

- The 3-4 weeks interval between the injections: please explain how you chose this time interval.

There is no consensus or scientific base for the number of PRP injections or the optimal interval. The patients had injections with 3-4 weeks based on recommendations from Arthrex. Due to the retrospective design this was not part of the study design.

- Symptom intensity of CMC1 OA is strongly related to the influence of psychosocial aspects; patients with greater symptoms of catastrophic thinking and depression have greater pain intensity. In many multivariable analysis, these are the strongest contributors to several outcomes including pain (see papers of Becker et al., Wilkens et al., or Prof. Ring). At least, this must be mentioned as it could lead to a potential bias in the findings of the current paper.

We agree with the reviewer and we have no included high pre-injection pain as a predictor in the analysis. The issue is also discussed in line 162-166. Although the above mentioned authors have produced many interesting articles, we could not find a suitable reference from these specific authors for this particular issue.

- How did you estimate an SD of 2 points for NRS pain?

SD 2 was estimated based on patient-rated pain in a large sample of patients planned for surgery for thumbbase osteoarthritis (Wilcke et al.) with a mean pain on load of 76 (SD 17) of 100 and the small study of Loibl et al; pain VAS 4.0 (SD 2.4) at 3 months after a PRP injection. This is now stated more clearly in line 76-77. In retrospect, the estimation was a bit low since the SD (which we do not present in the manuscript that reports median and IQR) of pain on load after 3 months were 3 corresponding to a required sample of 20 so we don’t think the study is underpowered.

- What where the inclusion criteria or selection criteria for patients to receive a PRP injection?

The selection criteria were osteoarthritis in the thumbbase or STT-joint. This is now pointed out in line 51.

Results & Discussion:

- Please write out "thirty-three" and other numbers that are at the beginning of a sentence.

This is now corrected.

- Line 111-112: these results don't exceed the MCID. Although there is some variety among studies about the MCID for pain scores (NRS/VAS), most agree that an improvement of 1 point is not enough to reach an MCID in outcome (Danoff 2018, Lee 2003). Even the study referred to in this manuscript (Salaffi et al.) supports the use of a "much better" improvement on pain relief as a clinically important outcome: and that is 2 points. I think the authors must revise this point and their conclusion.

According to reviewer #1:s concern about analyses being too simple, we have now remade them I cooperation with a statistician using a GEE model for longitudinal data with the possibility to correct for possible predictors. Interesting, this analysis showed no significant impact of PRP injection. Hence the conclusion and discussion are quite extensively revised.

Attachment

Submitted filename: Response to review PLOSone.docx

Decision Letter 1

Gabriel de Araújo

6 Dec 2021

PONE-D-21-21631R1Effects of intra-articular Platelet-Rich Plasma (PRP) injections on osteoarthritis in the thumb basal joint and scaphoidtrapeziotrapezoidal joint.PLOS ONE

Dear Dr. Wilcke,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 20 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Gabriel de Araújo, M.D., MSc

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Partly

Reviewer #3: No

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: I would recommend to accept this paper. However, one more suggestion:

* The conclusion of this paper is that PRP injections do not lead to pain relief, decrease of physical limitations or improvement of strength. The last paragraph of the discussion however, seems like a plea for the harmless use of PRP injections. Please look at this again. And delete the last sentence: "Although this study has methodological flaws, and it is important to test PRP in randomized placebo-controlled studies, our study results suggest that PRP injections have no effect on pain intensity, physical limitations, or thumb strength among patients with osteoarthritis in the thumb basal joint or STT-joint."

Reviewer #3: Thank you for the opportunity to review this paper.

The present paper is a 29-patient retrospective case series on the use of PRP in the treatment of thumb basal joint and STT joint OA. The authors observed a significant but small effect in terms of pain relief for osteoarthritis in the thumb basal joint or STT-joint.

The paper is in general well written and easy to follow. However, it has several methodological issues.

I credit the authors for prospective data collection. However, I cannot see why the authors did not define clear study objective/question and a study protocol a priori in order to collect a prospective case series. This leads to several shortcomings.

Perhaps the biggest concern is the lack of explicit inclusion and/or exclusion criteria which leads to major heterogeneity between participants: Both thumb basal joint and STT arthrosis (in my opinion, these conditions may be related to different biomechanical changes), age 34-86, posttraumatic or primary arthrosis (?), the duration of symptoms before treatment, pre-treatment pain intensity (no borders for inclusion/exclusion), associated conditions that might affect the result (e.g. small joint arthritis in general, thumb MCP arthritis), previous trauma or surgery of the hand/wrist and treatment of contralateral TMC/STT joint arthritis (successful non-operative/operative treatment of contralateral TMC/STT might affect patients expectations).

While the authors have assessed the severity of the arthritic changes - in my opinion it is as important to assess the joint congruency as the thumb basal joint might be clinically stable, instable or chronically subluxated - which might affect the outcome of the injection as the biomechanical basis of the disease might be different.

Another concern lies in the preparation of PRP - how rich is platelet-rich? No laboratory testing is made to control for the quality of the agent. Moreover, how do the authors believe that the quantity (0,5-2ml) of PRP affects the outcome? How was the interval between treatments decided? The regulatory aspects of the use of PRP for TMC and STT OA should also be declared.

The enrollment lasted from sep 2018 to sep 2019. Was it a consecutive series? Was the enrollment based on patient preference? How many patients declined? Were there any exclusion criteria?

Post-treatment regimen? The authors state that “The patients could resume work and daily activities immediately after the injection as tolerated.” - did the patients use a splint? Was there any hand exercise regimen? The authors report that two patients were prescribed pain medication at first injection, whereas 20 did not use any pain medication. Seven patients used pain medication for “unrelated reasons” All of these might significantly affect the outcome as the post-treatment protocol was not defined.

In the statistics paragraph the authors have presented a power calculation. A post-hoc power calculation seems off, why not just look at 95% CI? Why not repeated measures analysis of variance?

The results are very brief and mainly presented without numbers (percentage, SD, IQR, 95% CI) or significance levels. Lines 111-114 are not results per se but patient characteristics (a methodological concern). The minimally clinically important difference for pain presented in power calculation is 2 points (2 SD). However, the authors interpret a 1-point decrease in NRS a “substantial improvement”. How is this clinically relevant? The patients reported the pain to be “slightly better” - which could represent treatment bias and reflect the expectations of the patients. Patient acceptable symptom state (PASS) would better reflect the clinical outcome as PASS is the highest symptom level at which patients consider themselves well.

Moreover, the authors report that 15 patients requested a new PRP injection, and two patients wished for a corticosteroid injection at the follow-up 4 months after the first injection. Thus, at least 58% of the patients were probably not happy with the treatment. Was surgery an option? What about the 42%, what happened then? I would be interested if the treatment reduces the number of surgeries in the long-term. As the authors point out in the introduction - successful conservative treatment that delays or reduces the need for surgery is of great value. However, the present paper does not give any clinically relevant information on the matter as the results are very short term.

The subject of the present manuscript is very welcome as an increasing interest in biologic agents - as nonoperative treatment modalities or to augment surgical procedures - has been observed in recent years. However, the methodological shortcomings of the present paper make it hard to support the publication of this paper.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Mar 8;17(3):e0264203. doi: 10.1371/journal.pone.0264203.r004

Author response to Decision Letter 1


10 Dec 2021

Reviewer #2: I would recommend to accept this paper. However, one more suggestion:

* The conclusion of this paper is that PRP injections do not lead to pain relief, decrease of physical limitations or improvement of strength. The last paragraph of the discussion however, seems like a plea for the harmless use of PRP injections. Please look at this again. And delete the last sentence: "Although this study has methodological flaws, and it is important to test PRP in randomized placebo-controlled studies”, our study results suggest that PRP injections have no effect on pain intensity, physical limitations, or thumb strength among patients with osteoarthritis in the thumb basal joint or STT-joint."

According to the reviewer’s suggestion, we have deleted the last sentence “Although this study has methodological flaws, and it is important to test PRP in randomized placebo-controlled studies.”

Reviewer #3: Thank you for the opportunity to review this paper.

I credit the authors for prospective data collection. However, I cannot see why the authors did not define clear study objective/question and a study protocol a priori in order to collect a prospective case series. This leads to several shortcomings.

We agree with the reviewer that a prospective case-series would have been preferable. However, this is a retrospective study based on medical protocols.

Perhaps the biggest concern is the lack of explicit inclusion and/or exclusion criteria which leads to major heterogeneity between participants: Both thumb basal joint and STT arthrosis (in my opinion, these conditions may be related to different biomechanical changes), age 34-86, posttraumatic or primary arthrosis (?), the duration of symptoms before treatment, pre-treatment pain intensity (no borders for inclusion/exclusion), associated conditions that might affect the result (e.g. small joint arthritis in general, thumb MCP arthritis), previous trauma or surgery of the hand/wrist and treatment of contralateral TMC/STT joint arthritis (successful non-operative/operative treatment of contralateral TMC/STT might affect patients expectations).

We agree that this is a weakness with the retrospective design as discussed in line 169-176. On the other hand, the wide inclusion criteria make the result generalizable and there is no comparison between groups that would be biased by the heterogeneity.

While the authors have assessed the severity of the arthritic changes - in my opinion it is as important to assess the joint congruency as the thumb basal joint might be clinically stable, instable or chronically subluxated - which might affect the outcome of the injection as the biomechanical basis of the disease might be different.

This is an interesting point. However, since joint stability in thumb base osteoarthritis was not a variable recorded in the medical records, the effect if the joint stability could not be assessed.

Another concern lies in the preparation of PRP - how rich is platelet-rich? No laboratory testing is made to control for the quality of the agent.

Testing the concentration is not possible given the retrospective design. This is a pragmatic study of the effect of PRP prepared with a commercial kit. As the reviewer hints, the concentration may theoretically affect the effect of PRP, and this is discussed in line 132-34.

Moreover, how do the authors believe that the quantity (0,5-2ml) of PRP affects the outcome?

We have not included injected quantity as a covariate in the analysis since two different joints with different sizes (CMC1 and STT) were treated and we believe that quantity would be difficult to assess as a covariate. Therefore, we cannot say anything about the potential effect of the injected quantity.

How was the interval between treatments decided? The regulatory aspects of the use of PRP for TMC and STT OA should also be declared.

The interval of interval of 3-4 weeks was recommended by the manufacturer (Artrex). This is now stated in line 52. There are no regulatory aspects of PRP as discussed in line 180-1.

The enrollment lasted from sep 2018 to sep 2019. Was it a consecutive series? Was the enrollment based on patient preference? How many patients declined?

As described in line 45-48, all patients that received PRP treatment for radiologically and clinically verified osteoarthritis in the thumb basal joint or STT-joint between September 1st2018 and September 30th2019 were included. This is not a prospective study and hence, there was no invitation to participate in a study.

Were there any exclusion criteria?

Exclusion criteria was lack of data as describes in line 62-63 “Patients that did not attend the assessment after four months were excluded due to lack of data.“. We have added the sentence “There were no other exclusion criteria.” To clarify this.

Post-treatment regimen? The authors state that “The patients could resume work and daily activities immediately after the injection as tolerated.” - did the patients use a splint?

We have no information of whether and to what extent the patients used splints. This is now mentioned as a weakness in the discussion line 169-73.

Was there any hand exercise regimen? The authors report that two patients were prescribed pain medication at first injection, whereas 20 did not use any pain medication. Seven patients used pain medication for “unrelated reasons” All of these might significantly affect the outcome as the post-treatment protocol was not defined.

There was no post-injection hand exercise protocol. This is now stated in line 55-56. The use of pain killers was included as a possible predictor in the model. We have added the sentence “Manually demanding work, affected joint, and use of analgesic did not affect the outcome variables.” in line 109-110 to clarify that these included predictors in the model did not have an effect.

In the statistics paragraph the authors have presented a power calculation. A post-hoc power calculation seems off, why not just look at 95% CI? Why not repeated measures analysis of variance? The power calculation was performed prior to the analysis to estimate if there were enough available patients to enable a meaningful evaluation of this sample.

GEE is more efficient and flexible than Repeated measures ANOVA. GEE is an extension of generalized linear models such as RM-ANOVA to cover repeated measures and other forms of dependent data and can handle categorical outcome; non-normal and non-linear data.

The results are very brief and mainly presented without numbers (percentage, SD, IQR, 95% CI) or significance levels.

Could it be that the reviewer has read the first version and not the revised manuscript? Line 99-109 are all results with numbers; beta coefficient (β) with 95%CI.

Lines 111-114 are not results per se but patient characteristics (a methodological concern).

Is this the correct lines or do they refer to the non-revised manuscript? Lines 111-114:

“months after the first injection. There were no recorded infections or other adverse events.

Discussion

We could not find a significant effect on patient-reported pain, hand disability or strength in”

In the original, non-revised manuscript line 111-114 was:

“22 patients had used a splint prior to the PRP treatment, and 20 patients had previously tried corticosteroid injections. Two patients were prescribed analgesics for pain in the thumb base or STT-joint at/in conjunction with the first injection, 7 patients frequently used analgesics for unrelated causes and 20 patients were not prescribed any analgesics during the study period.”

If the reviewer addresses the lines in the original manuscript, we do not really agree. This is a description of the sample and that type of information is usually presented in result and we do not think that this information belongs under Methods.

The minimally clinically important difference for pain presented in power calculation is 2 points (2 SD). However, the authors interpret a 1-point decrease in NRS a “substantial improvement”. How is this clinically relevant?

We do not recognize this from the current manuscript, and we are concerned that the reviewer refers to the original and not the current revised manuscript?

Line 72-74: In patients with chronic musculoskeletal pain, a reduction of two points in the NRS is considered as a substantial improvement (“much better”) by the patients and is recommended as a clinically important outcome [15].

Line 119-121: However, even when possible confounders were not taken into account, the mean individual reduction in pain NRS did not amount to two points (table 2), corresponding to a substantial improvement [15].

The patients reported the pain to be “slightly better” - which could represent treatment bias and reflect the expectations of the patients. Patient acceptable symptom state (PASS) would better reflect the clinical outcome as PASS is the highest symptom level at which patients consider themselves well.

Again, we do not recognize this from the current manuscript, and we are concerned that the reviewer refers to the original and not the revised manuscript?

PASS seems like a good and relevant concept and a good a complementary measure to MCID but this was not used in the medical records and as to our knowledge there are no published cut-off value for osteoarthritis in the hand/wrist.

Moreover, the authors report that 15 patients requested a new PRP injection, and two patients wished for a corticosteroid injection at the follow-up 4 months after the first injection. Thus, at least 58% of the patients were probably not happy with the treatment. Was surgery an option? What about the 42%, what happened then? I would be interested if the treatment reduces the number of surgeries in the long-term. As the authors point out in the introduction - successful conservative treatment that delays or reduces the need for surgery is of great value. However, the present paper does not give any clinically relevant information on the matter as the results are very short term.

We cannot provide any information about further treatment including operation. This study does not give any information about the long-term effect in terms om reduced number of operation but only the short-term results as stated in line 5, 41, 117, 176.

The subject of the present manuscript is very welcome as an increasing interest in biologic agents - as nonoperative treatment modalities or to augment surgical procedures - has been observed in recent years. However, the methodological shortcomings of the present paper make it hard to support the publication of this paper.

We agree that this study has shortcomings. But at this time when PRP is widely administered despite limited evidence of its effect and reports may be affected by commercial interests, we believe that it is important to publish all available clinical results.

Attachment

Submitted filename: Rebuttal letter 2 PLOSone.docx

Decision Letter 2

Gabriel de Araújo

7 Feb 2022

Effects of intra-articular Platelet-Rich Plasma (PRP) injections on osteoarthritis in the thumb basal joint and scaphoidtrapeziotrapezoidal joint.

PONE-D-21-21631R2

Dear Dr. Wilcke,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Gabriel de Araújo, M.D., MSc

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The manuscript is well written and value. Besides that, I agree that all reviewers comments would improve the scientific quality of you study. For this reason, I am sending the reviewers suggestions for your appreciation.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #4: (No Response)

Reviewer #5: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #4: Partly

Reviewer #5: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #4: Yes

Reviewer #5: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #4: Yes

Reviewer #5: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #4: Yes

Reviewer #5: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #4: Thank you for the possibility to review this manuscript. As the authors report, there are few studies of the effect of PRP on osteoarthritis in the hand. This could be interesting work. However, some minor issues should be addressed.

The results section could be further explored by the authors.

The data described in lines 87 to 98 could be presented in a table, including the respective percentage of each characteristic.

Line 95 - The timing of corticosteroid use prior to PRP treatment may affect results. Considering that the majority of patients used corticosteroids (n=20), it is necessary to describe the period of time of use before treatment with PRP.

Table 2, considering the small number of the sample and the variability in the scores, it is important to present the percentage of improvement among the patients. Another strategy is to present the average of the differences between the moments.

Line 112- The authors described that 16 patients (57%) answered “yes” to the question whether they experienced a positive effect from the injections. It is necessary to explore who these patients are. Are there characteristics associated with this response (age, sex...)?

The subject of the present study is interesting and “polemical”, since there is little evidence on the subject. The subject of the present study is interesting and controversial, since there is little evidence on the subject. However, considering the limitations of the study (sample number and retrospective data), a detailed description of the results is necessary.

Reviewer #5: The Authors present a retrospective analysis about PRP injection for CMC-I or STT osteoarthritis.

The topic is interesting and relevant for the clinicians. The manuscript is well written and easy to read. The corrected version already take into account the previous comments.

The only two remaining problems that cannot bee changed are:

- the real composition of the injected PRP. It was obtained with a commercial kit and there is no way to check what was injected. In my opinion the technique is well described and could b reproduced easily.

- the amount injected. It is often difficult to inject a significant amount in the CMC-I and STT due to the small joint space and the arthritic changes and it is possible that the efficacy is dose-dependent. In the knee, a joint with a much larger intrarticular volume, the positive effect could be demonstrated. Future studies should address this issue.

Despite these two points I recommend to accept the paper.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #4: No

Reviewer #5: No

Acceptance letter

Gabriel de Araújo

28 Feb 2022

PONE-D-21-21631R2

Effects of intra-articular Platelet-Rich Plasma (PRP) injections on osteoarthritis in the thumb basal joint and scaphoidtrapeziotrapezoidal joint.

Dear Dr. Wilcke:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Gabriel de Araújo

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Dataset

    (XLSX)

    Attachment

    Submitted filename: Response to review PLOSone.docx

    Attachment

    Submitted filename: Rebuttal letter 2 PLOSone.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES